RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene ...
Fintel reports that on October 16, 2025, Chardan Capital initiated coverage of Opus Genetics (NasdaqCM:IRD) with a Buy ...
Opus Genetics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024. The low is $100 issued by Deutsche Bank on August 5, ...
TipRanks on MSN
Opus Genetics initiated with a Buy at Chardan
Chardan initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target The firm cites the commercial potential of the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback